Kate Knibbs is a senior writer at WIRED, covering the human side of the generative AI boom and exploring how new technology shapes the arts, entertainment, and media industries. With a background that includes roles at The Ringer and Gizmodo, she delves into themes such as artificial intelligence, social issues, and the intersection of technology with law and healthcare. Kate's work has been featured in WIRED Middle East, Editor & Publisher Magazine, Ars Technica, and several other notable publications.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Kate Knibbs covers a wide range of topics, including content & publishing, entertainment news, health, and technology. Her coverage frequently includes cited data and reviews. Given this information, she is likely to be interested in pitches that offer unique insights backed by credible data or provide access to exclusive reviews.
Pitches related to emerging trends in the areas of parenting, abortion pills (women's health), artificial intelligence (AI), openAI developments, tech ethics (e.g., deepfake), internet culture/social media platforms like TikTok may align well with her coverage interests.
Considering Kate’s diverse thematic focus without specific geographic constraints suggests that offering global perspectives on relevant issues could increase the appeal of your pitch.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kate Knibbs, Emily Mullin
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it's too difficult to do safely. It's the latest escalation in a brewing war between pharmaceutical companies and compounders.
The blogging platform Medium is facing an influx of AI-generated content. CEO Tony Stubblebine says it “doesn't matter” as long as nobody reads it.
By: Max G. Levy, Kate Knibbs, Makena Kelly, Angela Watercutter, Julian Chokkattu, Matt Kamen, Virginia Heffernan, Matt Burgess, Brenda Stolyar, Tess Owen, Vittoria Elliott
On’s robot created its new Cloudboom Strike LS performance shoes on-site in three minutes.
By: Kate Knibbs
An SEO agency owner says he is “very depressed” after one of his AI-assisted Halloween parade listings misled revelers in Dublin, Ireland.
By: Kate Knibbs
Prediction markets like Kalshi beat pollsters in forecasting the 2024 US election. Mansour now says financial marketplaces are the future of political prognostication.
By: Kate Knibbs
A judge tossed out a case against OpenAI brought by Alternet and Raw Story, in what could be a significant ruling in the larger battle between AI companies and publishers.
By: Kate Knibbs
A judge tossed out a case against OpenAI brought by Alternet and Raw Story, in what could be a significant ruling in the larger battle between AI companies and publishers.
An analysis of Substack’s top newsletters estimated that around 10 percent publish AI-generated or AI-assisted content.
GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions online, despite a lack of evidence that they work.
photo of New York Times Says OpenAI Erased Potential Lawsuit Evidence image As part of an ongoing copyright lawsuit, The New York Times says it spent 150 hours sifting through OpenAI’s training data looking for potential evidence—only for OpenAI to delete all of its work.
(833) 317-6278 
